BRAF and melanoma: Additionally, of note is that, within the current analysis, the patient populations differed with respect to BRAF mutation status (a known prognostic factor in melanoma): CheckMate 066 enrolled patients with BRAF wild-type disease, whereas CheckMate 067 and 069 enrolled patients with both mutant and wild-type disease.